Menu UF Health Home Menu
 

Jürgen Bulitta, Ph.D.

Jürgen Bulitta

Associate Professor

Pharmaceutics

OFFICE: 6550 Sanger Road, Office 475, Orlando FL 32827

EMAIL: jbulitta@cop.ufl.edu

PHONE: 407-313-7010

CV: Link to CV

 

Education

  • Ph.D., Institute for Biomedical and Pharmaceutical Research in Germany and Julius-Maximilians-University of Würzburg, Germany
  • M.Sc., Chemistry, Friedrich-Alexander-University Erlangen-Nürnberg, Germany

Biographical Sketch

Jürgen Bulitta, Ph.D., joined the Center for Pharmacometrics and Systems Pharmacology in the department of pharmaceutics at the College of Pharmacy. As an associate professor, he is supported by the University of Florida’s Preeminence program in drug discovery and development. Prior to joining UF, he worked as a senior research fellow and won peer-reviewed fellowships from the Australian equivalents of the National Institutes of Health (NHMRC) and the National Science Foundation (ARC), at Monash University in Melbourne, Australia.

Bulitta’s research focuses on multidrug-resistant bacterial “superbugs,” which present one of the three most serious threats to human health. To combat this global health crisis, his research goals are to discover and develop new antibiotics based on mechanistic biological insights, which his group generated over the last decade, and to develop and rationally optimize novel antibiotic dosing strategies. He was awarded 10 peer-reviewed grants from the National Institutes of Health and the Australian equivalents of NIH and NSF and 29 collaborative projects within the pharmaceutical industry totaling $13 million. He has published 86 peer-reviewed papers and contributed to more than 90 phase I-IV clinical trials. He won the Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics from the European Federation for Pharmaceutical Sciences (EUFEPS) and the 2012 Denis Wade Johnson & Johnson New Investigators Award from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT).

Affiliations

  • American Society for Microbiology (ASM)
  • American Society of Pharmacometrics (ASoP), founding member
  • American Association of Pharmaceutical Scientists (AAPS)
  • German Pharmaceutical Society (DPhG)
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
  • German National Academic Foundation (“Studienstiftung des Deutschen Vokes”)

Research Interests

  • Drug discovery, development and optimal patient therapies
  • Pharmacokinetics, pharmacodynamics, translational pharmacology
  • Infectious diseases, multidrug-resistant bacteria, non-replicating persister phenotype
  • Beta-lactams, polymyxins, aminoglycosides and other antibiotics
  • Penicillin-binding proteins (PBPs)
  • Synergistic antibiotic combinations to maximize bacterial killing and minimize resistance
  • Dynamic infection models (including the hollow fiber system), emergence of resistance
  • Pharmacometrics, population modeling, and quantitative systems pharmacology
  • S-ADAPT and SADAPT-TRAN

Select Publications

Rationally Optimizing Antibiotic Combination Therapy

Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. Novel approach to optimising synergistic carbapenem plus aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59:2286-98. PMID: 25645842

Ly NS, Bulitta JB, Rao GG, Holden PN, Landersdorfer CB, Rao GG, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time-course of synergistic killing and resistance prevention. J Antimicrob Chemother. 2015; 70:1434-42. PMID: 25712313

Landersdorfer CB, Ly NS, Xu H, Tsuji BT, Bulitta JB. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother. 2013; 57:2343-51. PMID: 23478962

Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. Relevance of Pharmacokinetic and Pharmacodynamic Modelling to Clinical Care of Critically Ill Patients. Current Pharmaceut Biotechnol 2011; 12:2044-61. PMID: 21554212

Quantitative Modeling of the Mechanisms of Antibiotic Action and Prevention of Resistance

Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother. 2015; 59:2315-27. PMID: 25645838

Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. Application of Pharmacokinetic-Pharmacodynamic Modeling and Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus from the Dead, Clin Infect Dis 2011; 52:S513-9. PMID: 21546628

Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, RE D’Hondt, Jusko WJ, Forrest A, Tsuji BT. High inoculum Pseudomonas aeruginosa attenuates colistin bactericidal activity characterized by a mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54:2051-62. PMID: 20211900

Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime Against Pseudomonas aeruginosa, Antimicrob Agents Chemother 2009; 53:46-56. PMID: 18852268

Human Population Pharmacokinetics and Pharmacodynamics of Antibiotics

Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 2014; 58:2334-4. PMID: 24514086

Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG. Population Pharmacokinetics of Fusidic Acid: Rationale for Front-loaded Dosing Regimens due to Auto-inhibition of Clearance. Antimicrob Agents Chemother. 2013; 57:498-507. PMID: 23147726

Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate (tedizolid) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55:583-92. PMID: 21115795

Bulitta JB, Landersdorfer CB, Hüttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sörgel U. Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrob Agents Chemother 2010; 54:1275-82. PMID: 20065059

Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51:2497-507. PMID: 17485505

Anti-Infective Pharmacodynamics – Experimental Models:

Rees VE, Bulitta JB, Nation RL, Tsuji BT, Sörgel F, Landersdorfer CB. Shape does matter: Short high-concentration exposure minimises resistance emergence for fluoroquinolones; J Antimicrob Chemother. 2015; 70:818-26. PMID: 25381167

Lee HJ; Bergen PJ, Bulitta JB, Tsuji BT, Forrest A, Nation RL, Li J. Colistin and rifampicin combination: synergistic activity against multidrug-resistant Acinetobacter baumannii in an in vitro PK/PD model. Antimicrob Agents Chemother 2013; 57:3738-45. PMID: 23716052

Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 2012; 67:2182-90. PMID: 22685161

Tsuji BT, Brown T, Parasrampuria R, Brazeau D, Forrest A, Kelchlin P, Holden P, Peloquin C, Hanna D, Bulitta JB. Front-Loaded Linezolid Regimens Results in Increased Killing and Suppression of the Accessory Gene Regulator system of Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:3712-9. PMID: 22526313

Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. The Effect of Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother 2011; 55:1747-53. PMID: 21263045

Pharmacometic Approaches and Tools

Bulitta JB, Bingölbali A, Shin BS, Landersdorfer CB. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS Journal 2011; 13:201-11. PMID: 21369876

Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS Journal 2011; 13:212-26. PMID: 21374103

Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sörgel F. A New Semi-Physiological Absorption Model to Assess the Pharmacodynamic Profile of Cefuroxime Axetil using Nonparametric and Parametric Population Pharmacokinetics, Antimicrob Agents Chemother 2009; 53:3462-71. PMID: 19528278

Landersdorfer CB, Kinzig M, Hennig FF, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F, Gusinde J. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrob Agents Chemother 2009; 53:2074-81. PMID: 19223648

Cheah S-E, Li J, Nation RL, Bulitta JB. Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Antimicrob Agents Chemother 2015; 59:381-8. PMID: 25367905